



## CONTACTS

Elizabeth Larkin  
Ikaria  
908-238-6645  
[liz.larkin@ikaria.com](mailto:liz.larkin@ikaria.com)

Jason Rando  
The Ruth Group  
646-536-7025  
[jrando@theruthgroup.com](mailto:jrando@theruthgroup.com)

## LOTA ZOTH ELECTED TO IKARIA BOARD AND NAMED AUDIT COMMITTEE CHAIR

**Clinton, NJ, January 22, 2008** – Ikaria Holdings, Inc., a fully integrated critical care biopharmaceutical company, announced today that Lota S. Zoth has been elected as an independent member of the company's Board of Directors. Ms. Zoth, the former Chief Financial Officer of MedImmune, will chair the Ikaria Audit Committee.

"We are very fortunate to have an executive with Lota's background and qualifications joining our Board at a very important time in the company's history," said David Shaw, Chairman of the Ikaria Board of Directors. "Lota's deep understanding of financial and accounting issues, in addition to her senior leadership experience in the pharmaceutical business, make her a superb fit for Ikaria."

Ms. Zoth served as MedImmune's Chief Financial Officer from 2004 until mid 2007, when MedImmune was acquired by AstraZeneca. Prior to that, Ms. Zoth served as Chief Accounting Officer of MedImmune, PSINet and Sodexo Marriott, all publicly traded companies. Ms. Zoth began her career as an auditor with Ernst & Young, and went on to management positions in financial reporting and controllership at PepsiCo and Marriott International. Ms. Zoth is a CPA, and holds a BBA, summa cum laude, in accounting from Texas Tech University.

### **About Ikaria Holdings, Inc.**

Ikaria Holdings, Inc. is a fully integrated biotherapeutics company focused on the development and commercialization of innovative in-hospital pharmaceutical products and drug/device combinations for the critically ill. The company's product, INOmax<sup>®</sup> (nitric oxide) for inhalation, is an FDA-approved drug for the treatment of hypoxic respiratory failure in term and near-term newborns. The drug also is approved by regulatory authorities and used in Canada, Europe, Australia and Latin America. In addition to marketing and selling its INOmax product, Ikaria is engaged in both Phase II trials with Covox<sup>®</sup> (carbon monoxide) for inhalation and Phase I trials with hydrogen sulfide (H<sub>2</sub>S) for various indications. Ikaria has a staff of over 300 people and is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI and manufacturing in Port Allen, LA. For more information on Ikaria, please visit [www.ikaria.com](http://www.ikaria.com).

###